DK3449939T3 - Farmaceutisk sammensætning til at hæmme metastase af kræft, omfattende, som aktiv ingrediens, antistof som specifikt binder til epidermal vækstfaktorreceptor - Google Patents

Farmaceutisk sammensætning til at hæmme metastase af kræft, omfattende, som aktiv ingrediens, antistof som specifikt binder til epidermal vækstfaktorreceptor Download PDF

Info

Publication number
DK3449939T3
DK3449939T3 DK16900546.9T DK16900546T DK3449939T3 DK 3449939 T3 DK3449939 T3 DK 3449939T3 DK 16900546 T DK16900546 T DK 16900546T DK 3449939 T3 DK3449939 T3 DK 3449939T3
Authority
DK
Denmark
Prior art keywords
metastase
pharmaceutical composition
active ingredient
growth factor
factor receptor
Prior art date
Application number
DK16900546.9T
Other languages
English (en)
Inventor
Jong-Hwa Won
Yangmi Lim
Min-Kyu Hur
Original Assignee
Green Cross Corp
Mogam Inst Biomedical Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp, Mogam Inst Biomedical Res filed Critical Green Cross Corp
Application granted granted Critical
Publication of DK3449939T3 publication Critical patent/DK3449939T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK16900546.9T 2016-04-27 2016-04-27 Farmaceutisk sammensætning til at hæmme metastase af kræft, omfattende, som aktiv ingrediens, antistof som specifikt binder til epidermal vækstfaktorreceptor DK3449939T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2016/004418 WO2017188472A1 (ko) 2016-04-27 2016-04-27 표피 성장 인자 수용체에 특이적으로 결합하는 항체를 유효성분으로 포함하는 암의 전이 억제용 약학 조성물

Publications (1)

Publication Number Publication Date
DK3449939T3 true DK3449939T3 (da) 2022-05-02

Family

ID=60159801

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16900546.9T DK3449939T3 (da) 2016-04-27 2016-04-27 Farmaceutisk sammensætning til at hæmme metastase af kræft, omfattende, som aktiv ingrediens, antistof som specifikt binder til epidermal vækstfaktorreceptor

Country Status (13)

Country Link
US (1) US11198733B2 (da)
EP (1) EP3449939B1 (da)
JP (1) JP6701382B2 (da)
KR (1) KR102128556B1 (da)
CN (1) CN109195627B (da)
DK (1) DK3449939T3 (da)
ES (1) ES2912903T3 (da)
HR (1) HRP20220576T1 (da)
HU (1) HUE058745T2 (da)
LT (1) LT3449939T (da)
PL (1) PL3449939T3 (da)
SI (1) SI3449939T1 (da)
WO (1) WO2017188472A1 (da)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790164B2 (en) 2006-11-14 2010-09-07 Van Andel Research Institute Fragments of antibodies to epidermal growth factor receptor and methods of their use
KR101108642B1 (ko) 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
EP2566512A1 (en) * 2010-05-04 2013-03-13 Merrimack Pharmaceuticals, Inc. Antibodies against epidermal growth factor receptor (egfr) and uses thereof
KR20130083090A (ko) 2012-01-10 2013-07-22 강원대학교산학협력단 암 세포의 ｅｇｆｒ에 특이적으로 결합하는 항체 및 이의 용도
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CA2872018A1 (en) * 2012-05-17 2013-11-21 Sorrento Therapeutics, Inc. Antigen binding proteins that bind egfr
JP2015518872A (ja) 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用
CA2908819A1 (en) 2013-04-22 2014-10-30 Glycotope Gmbh Anti-cancer treatments with anti-egfr antibodies having a low fucosylation

Also Published As

Publication number Publication date
ES2912903T3 (es) 2022-05-30
US11198733B2 (en) 2021-12-14
EP3449939B1 (en) 2022-03-30
JP2019514909A (ja) 2019-06-06
CN109195627A (zh) 2019-01-11
CN109195627B (zh) 2022-09-09
HUE058745T2 (hu) 2022-09-28
LT3449939T (lt) 2022-05-25
EP3449939A1 (en) 2019-03-06
US20190119388A1 (en) 2019-04-25
JP6701382B2 (ja) 2020-05-27
HRP20220576T1 (hr) 2022-06-10
EP3449939A4 (en) 2019-12-18
PL3449939T3 (pl) 2022-06-20
KR102128556B1 (ko) 2020-06-30
SI3449939T1 (sl) 2022-06-30
WO2017188472A1 (ko) 2017-11-02
KR20180137502A (ko) 2018-12-27

Similar Documents

Publication Publication Date Title
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
BR112015004489A2 (pt) composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto
DK3576788T3 (da) Farmaceutisk sammensætning med lavt ph, der omfatter t-celle-engagerende antistofkontruktioner
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
DK3470063T3 (da) Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme
DK2818482T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK2824114T3 (da) Farmaceutisk sammensætning til behandling af cancer
DK3727453T3 (da) Flydende sammensætning til administration
EP3450460C0 (en) MULTI-SPECIFIC BINDING CONJUGATE, RELATED PHARMACEUTICAL COMPOSITIONS AND USE
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
DK3634468T3 (da) Fast sammensætning til oral indgivelse
PT3357491T (pt) Composição farmacêutica para distribuir um fármaco aniónico
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.
DK2741763T3 (da) Sammensætning til kontrolleret ovariestimulering.
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112013031712A2 (pt) composto, composição farmacêutica, métodos para preparar um composto e para o tratamento de um distúrbio ou uma doença.
MA53106A (fr) Polymères liant les protons pour administration orale
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
BR112014008241A2 (pt) composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
ZA201605263B (en) Pharmaceutical composition for topical administration
HUE053736T2 (hu) ANTI-CD28, humanizált antitestek embereknek történõ beadásra kiszerelve
LT3256154T (lt) Farmacinė kompozicija, apimanti antikūną
BR112018002283A2 (pt) Composição para administração tópica a um sujeito, e, formulação tópica
BR112015012877A2 (pt) composto de fórmula, composição farmacêutica, uso do composto e método para o tratamento do câncer
BR112017002852A2 (pt) compostos de azetidiniloxifenilpirrolidina